Mabwell (Shanghai) Bioscience Co., Ltd. (SHA:688062)
China
· Delayed Price · Currency is CNY 33.93
-0.26 (-0.76%)
At close: Mar 9, 2026
SHA:688062 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Operating Revenue | 662.52 | 199.62 | 127.68 | 27.6 | 15.88 | Upgrade
|
| Other Revenue | - | 0.16 | 0.15 | 0.13 | 0.35 | Upgrade
|
| Revenue | 662.52 | 199.78 | 127.84 | 27.73 | 16.23 | Upgrade
|
| Revenue Growth (YoY) | 231.62% | 56.28% | 361.03% | 70.88% | 206.03% | Upgrade
|
| Cost of Revenue | - | 34.48 | 7.3 | 2.01 | 5.22 | Upgrade
|
| Gross Profit | 662.52 | 165.3 | 120.53 | 25.72 | 11 | Upgrade
|
| Selling, General & Admin | - | 405.2 | 368.36 | 267.62 | 189.16 | Upgrade
|
| Research & Development | - | 782.87 | 835.78 | 758.61 | 622.51 | Upgrade
|
| Other Operating Expenses | 1,619 | 4.42 | 3.8 | 1.88 | 0.8 | Upgrade
|
| Operating Expenses | 1,619 | 1,193 | 1,208 | 1,028 | 812.44 | Upgrade
|
| Operating Income | -956.16 | -1,027 | -1,087 | -1,002 | -801.44 | Upgrade
|
| Interest Expense | - | -57.78 | -13.35 | -10.3 | -6.41 | Upgrade
|
| Interest & Investment Income | - | 20.92 | 46.88 | 45.75 | 7.38 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.28 | -0.01 | 0.16 | -0.24 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.08 | -2.34 | -1.74 | -1.82 | 2.63 | Upgrade
|
| EBT Excluding Unusual Items | -957.24 | -1,066 | -1,056 | -968.59 | -798.07 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -3.73 | -4.69 | 1.08 | -0.23 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.11 | -0.01 | 0.33 | 2.06 | Upgrade
|
| Asset Writedown | - | - | -3.56 | - | - | Upgrade
|
| Other Unusual Items | - | 22.5 | 8.61 | 9.06 | 23.54 | Upgrade
|
| Pretax Income | -957.24 | -1,047 | -1,055 | -958.13 | -772.7 | Upgrade
|
| Income Tax Expense | 12.94 | -0.91 | 3.52 | - | - | Upgrade
|
| Earnings From Continuing Operations | -970.18 | -1,047 | -1,059 | -958.13 | -772.7 | Upgrade
|
| Minority Interest in Earnings | - | 2.65 | 5.38 | 2.89 | 3.11 | Upgrade
|
| Net Income | -970.18 | -1,044 | -1,053 | -955.23 | -769.59 | Upgrade
|
| Net Income to Common | -970.18 | -1,044 | -1,053 | -955.23 | -769.59 | Upgrade
|
| Shares Outstanding (Basic) | 399 | 400 | 399 | 391 | 299 | Upgrade
|
| Shares Outstanding (Diluted) | 399 | 400 | 399 | 391 | 299 | Upgrade
|
| Shares Change (YoY) | -0.18% | 0.24% | 1.93% | 30.74% | 5.32% | Upgrade
|
| EPS (Basic) | -2.43 | -2.61 | -2.64 | -2.44 | -2.57 | Upgrade
|
| EPS (Diluted) | -2.43 | -2.61 | -2.64 | -2.44 | -2.57 | Upgrade
|
| Free Cash Flow | - | -1,287 | -1,283 | -1,264 | -639.91 | Upgrade
|
| Free Cash Flow Per Share | - | -3.22 | -3.21 | -3.23 | -2.14 | Upgrade
|
| Gross Margin | 100.00% | 82.74% | 94.29% | 92.75% | 67.81% | Upgrade
|
| Operating Margin | -144.32% | -514.17% | -850.65% | -3615.06% | -4939.16% | Upgrade
|
| Profit Margin | -146.44% | -522.53% | -824.05% | -3445.00% | -4742.85% | Upgrade
|
| Free Cash Flow Margin | - | -643.96% | -1003.35% | -4559.01% | -3943.69% | Upgrade
|
| EBITDA | -859.31 | -930.36 | -1,013 | -937.96 | -739.4 | Upgrade
|
| EBITDA Margin | -129.70% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 96.85 | 96.85 | 74.43 | 64.43 | 62.04 | Upgrade
|
| EBIT | -956.16 | -1,027 | -1,087 | -1,002 | -801.44 | Upgrade
|
| EBIT Margin | -144.32% | - | - | - | - | Upgrade
|
| Revenue as Reported | - | 199.78 | 127.84 | 27.73 | 16.23 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.